NEWSROOM

MEDIA CONTACTS

 

media@galderma.com

Christian Marcoux, Chief Communications Officer: +41 76 315 26 50

Sébastien Cros, Corporate Communications Director: +41 79 529 59 85 

Filter news by date

11 . 22 . 2021

Galderma leads oral presentation on hyaluronic acid filler safety insights at ASDS 2021 Annual Meeting

9 . 30 . 2021

 

RESTYLANE®, the original stabilized hyaluronic acid filler, celebrates 25 years of unmatched achievement

9 . 29 . 2021

 

Galderma presents new nemolizumab data at EADV reinforcing rapid onset of action and consistent relief of symptoms for people with prurigo nodularis and atopic dermatitis

9 . 28 . 2021

 

Galderma to unveil ground-breaking data from across its leading dermatology portfolio and showcase major update for sensitive skincare brand CETAPHIL® at the 2021 EADV Congress

9 . 27 . 2021

 

Galderma and CETAPHIL® Announce Renewed Commitment to Environmental Sustainability and Social Impact Through New Clear Skies Initiative

9 . 23 . 2021

 

Galderma announces exclusive agreement with Sofregen to develop the next generation of biostimulator fillers using silk-based technology

9 . 9 . 2021

 

Galderma to present new data from leading aesthetics portfolio and launch RESTYLANE® EYELIGHT™ at AMWC 2021

6 . 28 . 2021

 

Sol-Gel Technologies and Galderma announce exclusive licenses for the commercialization of EPSOLAY® and TWYNEO® in the United States

6 . 11 . 2021

 

Alluzience®, the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe

5 . 19 . 2021

 

How Galderma's Environmental, Social and corporate Governance approach guides its roadmap for sustainable growth

5 . 11 . 2021

 

Galderma launches CETAPHIL® line for sensitive skin and a new DAYLONG® sun protection product in Switzerland

5 . 6 . 2021

 

New study reveals the impact of ‘hidden acne’ on quality of life

5 . 4 . 2021

 

Galderma launches new Multichannel Medical Education platform: Inaugural webinar series on the impact of mask wearing on skin diseases